Updated on 2022/05/17

写真a

 
SUZUKI Yuka
 
Organization
Nagoya University Hospital Anatomical Pathology Assistant Professor
Graduate School
Graduate School of Medicine
Title
Assistant Professor

Degree 1

  1. 博士(医学) ( 2017.11   名古屋大学 ) 

Research Areas 1

  1. Life Science / Tumor diagnostics and therapeutics

Education 1

  1. University of Occupational and Environmental Health, Japan

    2001.4 - 2007.3

Professional Memberships 3

  1. 日本リンパ網内系学会

  2. 日本臨床細胞学会

  3. 日本病理学会

 

Papers 36

  1. beta-catenin (CTNNB1) mutation and LEF1 expression in sinonasal glomangiopericytoma (sinonasal-type hemangiopericytoma) Reviewed

    Suzuki Yuka, Ichihara Shu, Kawasaki Tomonori, Yanai Hiroyuki, Kitagawa Satoshi, Shimoyama Yoshie, Nakamura Shigeo, Nakaguro Masato

    VIRCHOWS ARCHIV   Vol. 473 ( 2 ) page: 235 - 239   2018.8

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00428-018-2370-9

    Web of Science

    Scopus

    PubMed

  2. Clinicopathological analysis of 46 cases with CD4(+) and/or CD56(+) immature haematolymphoid malignancy: reappraisal of blastic plasmacytoid dendritic cell and related neoplasms Reviewed

    Suzuki Yuka, Kato Seiichi, Kohno Kei, Satou Akira, Eladl Ahmed E., Asano Naoko, Kono Michihiro, Kato Yuichi, Taniwaki Masafumi, Akiyama Masashi, Nakamura Shigeo

    HISTOPATHOLOGY   Vol. 71 ( 6 ) page: 972 - 984   2017.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/his.13340

    Web of Science

    Scopus

    PubMed

  3. PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without <i>PD-L1</i> 3’-UTR structural variations

    Takahara Taishi, Ishikawa Eri, Suzuki Yuka, Kogure Yasunori, Sato Akira, Kataoka Keisuke, Nakamura Shigeo

    Journal of Clinical and Experimental Hematopathology   Vol. advpub ( 0 )   2022.4

     More details

    Language:English   Publisher:The Japanese Society for Lymphoreticular Tissue Research  

    DOI: 10.3960/jslrt.21028

    PubMed

    CiNii Research

  4. Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells Reviewed

    Kawano Tasuku, Tsuyuki Yuta, Suzuki Yuka, Shimada Kazuyuki, Kato Seiichi, Takahara Taishi, Mori Mayuko, Nakaguro Masato, Sakakibara Ayako, Nakamura Shigeo, Satou Akira

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY   Vol. 45 ( 12 ) page: 1606 - 1615   2021.12

     More details

    Language:Japanese   Publisher:The American journal of surgical pathology  

    Primary adrenal diffuse large B-cell lymphoma (PA-DLBCL) is rare. We investigate 23 Japanese patients with PA-DLBCL to understand the clinicopathologic features and biological behavior of this disease. The 17 males and 6 females had a median age of 74 years (range: 40 to 86 y). Tumor cells harbored Epstein-Barr virus-encoded small RNA (EBER) in 9 (39%) samples, including samples from the 2 patients with methotrexate-associated B-cell lymphoproliferative disorder. Programmed cell death ligand 1 (PD-L1) expression was detected in tumor cells of 6 (26%) samples, including 1 EBER+ and 5 EBER- samples. Four (17%) patients exhibited an intravascular proliferating pattern, and all 4 patient samples showed positive staining for PD-L1 in tumor cells. Among those patients, 3 showed intravascular proliferating pattern accompanied by a diffuse extravascular proliferation of tumor cells, and 1 patient was diagnosed with intravascular large B-cell lymphoma. We divided the 23 patients into 3 groups: EBER+ (n=9, 39%), EBER-PD-L1+ (n=5, 22%), and EBER-PD-L1- (n=9, 39%). A comparison of the outcomes among the 3 groups showed significant differences in overall survival (P=0.034). The EBER+ group had the worst prognosis, and the EBER-PD-L1- group had the best prognosis. We also compared the outcomes among the 3 groups that received rituximab-containing chemotherapies. Both the overall survival and progression-free survival were significantly different among these groups (P<0.001 and P=0.002, respectively). In conclusion, we evaluated 3 types of PA-DLBCL and found that each had unique clinical, pathologic, and prognostic features. Our results suggested that immune senescence, iatrogenic immunodeficiency, and immune evasion contribute to the development of PA-DLBCL.

    DOI: 10.1097/PAS.0000000000001809

    Web of Science

    Scopus

    PubMed

  5. Left Upper Lobe Trisegmentectomy After Pulmonary Endarterectomy Reviewed

    Tsubouchi Hideki, Goto Masaki, Terazawa Sachie, Adachi Shiro, Suzuki Yuka, Usui Akihiko, Kondo Takahisa, Chen-Yoshikawa Toyofumi F.

    ANNALS OF THORACIC SURGERY   Vol. 112 ( 5 ) page: E361 - E363   2021.11

     More details

    Language:Japanese   Publisher:Annals of Thoracic Surgery  

    Major pulmonary resection has been successfully performed after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension in a few cases. A pulmonary nodule was detected in a 68-year-old man with a diagnosis of chronic thromboembolic pulmonary hypertension. After pulmonary hypertension was resolved with pulmonary endarterectomy, left upper lobe trisegmentectomy was performed for small lung cancer. Dissection of the pulmonary artery was carefully performed with a possibility of a fragile state on the arterial wall due to previous pulmonary endarterectomy. Pathologically, the arterial media with an uneven thickness was exposed to the vascular lumen in the resected pulmonary artery.

    DOI: 10.1016/j.athoracsur.2021.02.022

    Web of Science

    Scopus

    PubMed

  6. Interdigitating dendritic cell sarcoma of the spine: Hitherto undescribed lesion Reviewed

    Futatsuya Chizuru, Minato Hiroshi, Okayama Yurie, Katayanagi Kazuyoshi, Kurumaya Hiroshi, Matsumoto Yasuko, Fukuoka Makoto, Suzuki Yuka, Nakamura Shigeo

    PATHOLOGY INTERNATIONAL   Vol. 71 ( 9 ) page: 636 - 638   2021.9

     More details

    Language:Japanese   Publisher:Pathology International  

    DOI: 10.1111/pin.13139

    Web of Science

    Scopus

    PubMed

  7. Prognostic Value of Uncertain Resection for Overall Survival in Non-small Cell Lung Cancer. Reviewed

    Kadomatsu Y, Nakamura S, Ueno H, Goto M, Ozeki N, Fukumoto K, Fukui T, Suzuki Y, Chen-Yoshikawa TF

    The Annals of thoracic surgery     2021.8

     More details

    Language:English   Publisher:Annals of Thoracic Surgery  

    Background: In this study we evaluated the R(un) category proposed by the International Association for the Study of Lung Cancer (IASLC) for non-small cell lung cancer (NSCLC). Methods: We retrospectively reviewed the medical records of patients with NSCLC who underwent segmentectomy or lobectomy between 2014 and 2015 at our institution. Residual tumor (R) status was reclassified from the Union for International Cancer Control designation to the IASLC-proposed R classification of R0 and R(un). The underlying reasons for the R(un) reclassification were analyzed according to pathologic stage, lymph node status, and resected lobe. A Cox proportional hazard model was used to evaluate the impacts of R(un) categorization on overall survival. Results: Of 355 patients, 44.5% were reclassified as R(un). The most common reason for the reclassification was insufficient number of harvested lymph nodes or no station 7 lymph nodes. When stratified by tumor location, the absence of station 7 lymph nodes was especially prominent in both the right and left upper lung resections. In the multivariate Cox regression model, the IASLC R classification was associated with poor overall survival in node-positive patients (hazard ratio, 2.657; P =.016). Conclusions: Various factors resulted in reclassification to R(un) because the R(un) group was highly heterogeneous. Careful consideration is required to determine whether the R(un) classification can be used as an indicator of lymph node dissection quality. For advanced cases, the R(un) definition may be useful in predicting poor prognosis.

    DOI: 10.1016/j.athoracsur.2021.07.087

    Scopus

    PubMed

  8. Thymic mucinous adenocarcinoma: A case report

    Tsubouchi Hideki, Ozeki Naoki, Suzuki Yuka, Kawaguchi Koji, Fukui Takayuki, F. Chen-Yoshikawa Toyofumi

    The Journal of the Japanese Association for Chest Surgery   Vol. 35 ( 5 ) page: 547 - 552   2021.7

     More details

    Language:Japanese   Publisher:The Japanese Association for Chest Surgery  

    <p>A 61-year-old woman presented with a 44-mm well-circumscribed tumor in the anterior mediastinum on chest computed tomography. <sup>18</sup>F-Fluorodeoxyglucose positron emission tomography showed a high-level accumulation of <sup>18</sup>F-Fluorodeoxyglucose (standardized uptake value: 12.07). She underwent thymectomy with combined resection of partial pericardium. Histopathological findings showed that the tumor was a thymic mucinous adenocarcinoma (pT2N0M0 Stage II, and Masaoka stage III). After receiving adjuvant radiotherapy, she was in good health without any tumor recurrence at 6 months after surgery.</p>

    DOI: 10.2995/jacsurg.35.547

    CiNii Research

  9. Nodal EBV-positive polymorphic B cell lymphoproliferative disorder with plasma cell differentiation: clinicopathological analysis of five cases Reviewed

    Satou Akira, Tabata Tetsuya, Suzuki Yuka, Sato Yasuharu, Tahara Ippei, Mochizuki Kunio, Oishi Naoki, Takahara Taishi, Yoshino Tadashi, Tsuzuki Toyonori, Nakamura Shigeo

    VIRCHOWS ARCHIV   Vol. 478 ( 5 ) page: 969 - 976   2021.5

     More details

    Language:Japanese   Publisher:Virchows Archiv  

    Plasma cell differentiation (PCD) is frequently observed in some entities of non-Hodgkin B cell lymphoma, including both low-grade and high-grade lymphomas. However, except for plasmablastic lymphoma and primary effusion lymphoma, EBV+ B cell lymphoproliferative disorder (LPD) with PCD has not been well addressed due to its rarity. We clinicopathologically examined five cases of nodal EBV+ polymorphic B cell LPD with PCD (PBLPD-PCD) initially diagnosed as polymorphic EBV+ diffuse large B cell lymphoma, not otherwise specified (DLBCL-NOS) with PCD (n = 3) and methotrexate-associated B cell LPD (MTX-associated B-LPD) (n = 2). One case had a concomitant brain lesion which was clinically diagnosed as EBV-related encephalitis. This patient received therapy with vidarabine, and both the brain lesion and the nodal EBV+ PBLPD-PCD lesions disappeared. Another case was characterized by Mott cell differentiation. This case was the first reported case of EBV+ B cell lymphoma or LPD with Mott cell differentiation. The two cases of MTX-associated B cell LPD which arose in patients with rheumatoid arthritis spontaneously regressed after MTX cessation. TCRγ and IGH PCR analysis was performed in four cases. Two cases had TCRγ rearrangements, but no IGH rearrangements. The other two cases had no rearrangements in these genes. We concluded that nodal EBV+ PBLPD-PCD is rare, with heterogeneous characteristics. PCR analysis revealed that nodal EBV+ PBLPD-PCD may have only TCR clonality and no IGH clonality. Considering the partial or complete loss of CD20 expression on the tumor cells, this result may be confusing for accurate diagnosis of EBV+ PBLPD-PCD, and pathologists need to be aware of this phenomenon to avoid misdiagnosis.

    DOI: 10.1007/s00428-020-02967-6

    Web of Science

    Scopus

    PubMed

  10. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system Reviewed

    Tsuyuki Yuta, Ishikawa Eri, Kohno Kei, Shimada Kazuyuki, Ohka Fumiharu, Suzuki Yuka, Mabuchi Seiyo, Satou Akira, Takahara Taishi, Kato Seiichi, Miyagi Shohei, Ozawa Hiroyuki, Kawano Tasuku, Takagi Yusuke, Hiraga Junji, Wakabayashi Toshihiko, Nakamura Shigeo

    NEUROPATHOLOGY   Vol. 41 ( 2 ) page: 99 - 108   2021.4

     More details

    Language:Japanese   Publisher:Neuropathology  

    Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNS-DLBCL) is rare. Thirty-nine patients consecutively diagnosed as having PCNS-DLBCL were analyzed to highlight the prognostic value of the expression of programmed cell death ligand-1 (PD-L1) by neoplastic cells and immune cells in the microenvironment. They were positive for CD20 in all (100%), CD5 in two (5%), CD10 in nine (23%), BCL-2 in 27 (69%), BCL-6 in 34 (87%), and MUM-1 in 37 (95%). Only one case was positive for neoplastic PD-L1, with an unexpectedly long clinical course of 92 months. The remaining 38 cases were further divided into three groups based on the percentage of PD-L1+ cells among microenvironmental immune cells. Cutoffs of < 5%, 5–40%, and ≥ 40% successfully stratified mean prognoses with three-year overall survival (OS) of 21%, 63%, and 100% (P = 0.009), respectively. Progression-free survival (PFS) and OS were different between the groups with and without methotrexate (MTX)-containing chemotherapy (P = 0.007 and P < 0.001, respectively). Multivariate analysis identified three independent adverse factors of OS: PD-L1 negativity (< 5%) on microenvironmental immune cells (P = 0.027), deep structure involvement (P = 0.034), and performance status (PS) 2–4 (P = 0.009). The study showed that PD-L1 expression on immune cells in the microenvironment was associated with prognosis among patients with PCNS-DLBCL.

    DOI: 10.1111/neup.12705

    Web of Science

    Scopus

    PubMed

  11. Cutaneous extramedullary hematopoiesis in a patient with secondary myelofibrosis due to MPL gene mutation Reviewed

    Murase Y., Takeichi T., Tanahashi K., Marumo Y., Suzuki Y., Nakamura S., Akiyama M.

    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY   Vol. 35 ( 4 ) page: E257 - E259   2021.4

     More details

    Language:Japanese   Publisher:Journal of the European Academy of Dermatology and Venereology  

    DOI: 10.1111/jdv.16990

    Web of Science

    Scopus

  12. Clinicopathological analysis of neoplastic PD-L1-positive EBV(+)diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort Reviewed

    Takahara Taishi, Satou Akira, Ishikawa Eri, Kohno Kei, Kato Seiichi, Suzuki Yuka, Takahashi Emiko, Ohashi Akiko, Asano Naoko, Tsuzuki Toyonori, Nakamura Shigeo

    VIRCHOWS ARCHIV   Vol. 478 ( 3 ) page: 541 - 552   2021.3

     More details

    Language:Japanese   Publisher:Virchows Archiv  

    The programmed death 1 (PD1)/PD1 ligand (PD-L1) axis plays an important role in the pathogenesis of Epstein-Barr virus-positive diffuse large B cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS). Here, we describe PD-L1 expression by EBV+ DLBCL, NOS in order to evaluate its possible contribution to the pathogenesis of this tumor. The study included 57 cases of EBV+ DLBCL, NOS. The median patient age was 69 years and 95% (n = 54) were aged > 45. Extranodal lesions were present in 39 (69%) at initial diagnosis. PD-L1 expression (mAb SP142-positive staining) was present in more than 5% of tumor cells in only six cases (11%), in clear contrast to the 77% reported in cases aged under 45 years. Among the PD-L1+ cases, three were nodal lesions. All six PD-L1+ cases progressed in the 3 years after diagnosis and four of the six patients died of the disease within 2 years. PD-L1+ cases had significantly shorter PFS (P = 0.002) and relatively short OS (P = 0.26), compared with PD-L1− cases. EBV+ DLBCL, NOS in the elderly infrequently expressed PD-L1 and had poor prognosis. PD-L1 expression in EBV+ DLBCL, NOS of the elderly sheds light on the pathogenetic role of immune senescence.

    DOI: 10.1007/s00428-020-02901-w

    Web of Science

    Scopus

    PubMed

  13. Histiocytic and dendritic cell neoplasms: Reappraisal of a Japanese series based on t(14;18) and neoplastic PD-L1 expression Reviewed

    Okada Kanae, Takahara Taishi, Suzuki Yuka, Kohno Kei, Sakakibara Ayako, Satou Akira, Takahashi Emiko, Nakamura Shigeo

    PATHOLOGY INTERNATIONAL   Vol. 71 ( 1 ) page: 24 - 32   2021.1

     More details

    Language:Japanese   Publisher:Pathology International  

    Histiocytic and dendritic cell (H/DC) neoplasms are heterogeneous, originating from myeloid- or stromal-derived cells. Multiple reports describe the cross-lineage transdifferentiation of neoplastic B cells into H/DC neoplasms. Most such cases are from Western countries, and rarely from Japan or East Asia. Here we report 17 cases of H/DC neoplasms in Japanese patients, with analysis of t(14;18) by fluorescence in situ hybridization, and of neoplastic programmed death-ligand 1 (PD-L1) expression by immunostaining (clones SP142, E1J2J, and 28-8). These 17 cases were diagnosed according to the 2017 World Health Organization (WHO) classification, and included two histiocytic sarcomas (HS), two interdigitating cell (IDC) sarcomas, one Langerhans cell sarcoma, two dendritic cell sarcomas, and 10 follicular dendritic cell (FDC) sarcomas. No case had any past history of follicular lymphoma (FL). Two cases of HS and one IDC sarcoma, all of which were myeloid-driven, were found to exhibit t(14;18). In the latter case, at 30 months after IDC sarcoma diagnosis, FL development was detected. Three (30%) FDC sarcoma cases exhibited neoplastic PD-L1 expression with all the three PD-L1 antibody clones. This is the first report of t(14;18) and neoplastic PD-L1 expression on H/DC neoplasms among Japanese patients, each of which appeared to be associated with HS and FDC sarcoma, respectively.

    DOI: 10.1111/pin.13044

    Web of Science

    Scopus

    PubMed

  14. Follicular T-cell lymphoma mimicking lymphocyte-rich classic Hodgkin lymphoma: a case report of a diagnostic pitfall

    Sakakibara Ayako, Suzuki Yuka, Kato Harumi, Yamamoto Kazuhito, Sakata-Yanagimoto Mamiko, Ishikawa Yuichi, Furukawa Katsuya, Shimada Kazuyuki, Kohno Kei, Nakamura Shigeo, Satou Akira, Kato Seiichi

    Journal of Clinical and Experimental Hematopathology   Vol. 61 ( 2 ) page: 97 - 101   2021

     More details

    Language:Japanese   Publisher:The Japanese Society for Lymphoreticular Tissue Research  

    <p>Follicular T-cell lymphoma (FTCL), one of the nodal T-cell lymphomas with T follicular helper (T<sub><sup>FH</sup></sub>) phenotype, is an uncommon disease. The diagnosis of FTCL is challenging on the distinction from the morphological mimics mostly exemplified by follicular lymphoma. Here, we described a case of FTCL that mimicked lymphocyte-rich classic Hodgkin lymphoma (LRCHL). A 47-year-old male presented with cervical lymphadenopathy. The biopsy specimen demonstrated nodular lymphoid proliferation, which included scattered CD30+ CD15- CD20- PAX5 weakly+ Hodgkin and Reed-Sternberg (HRS)-like cells and a rich distribution of CD3+ CD4+ PD1+ T-cells. Epstein Barr virus was not detected in HRS-like cells, but it was detected in a small proportion of the scattered lymphocytes. The large cells were also negative for programmed cell death ligand 1, which appeared to be coincidental as described in our previous report of LRCHL. However, flow cytometry showed a CD3- CD4+ T-cell population that constituted 37.4% of all gated lymphocytes. A PCR analysis showed a clonal T-cell receptor-gamma gene rearrangement, but not a clonal immunoglobulin heavy chain gene rearrangement, and showed <i>RHOA</i> G17V mutation. The constellation of these findings led us to revise the diagnosis to FTCL. This result indicated that our case belonged to a relatively indolent subgroup of nodal peripheral T-cell lymphoma of T<sub><sup>FH</sup></sub> phenotype, which affects patients ≤60 years old, recently proposed by our group. This case report expands our understanding of the morphologic spectrum of FTCL and its clinicopathologic significance.</p>

    DOI: 10.3960/jslrt.20052

    Web of Science

    PubMed

    CiNii Research

  15. Lymphocyte-depleted classic Hodgkin lymphoma with primary extranodal disease: Two cases that highlight the combination of immunodeficiency and immune escape in the pathogenesis

    Tsuyuki Yuta, Kohno Kei, Inagaki Yuichiro, Sakai Yu, Kosugi Hiroshi, Takahashi Emiko, Suzuki Yuka, Shimada Satoko, Kato Seiichi, Takahara Taishi, Satou Akira, Shimoyama Yoshie, Nakamura Shigeo, Asano Naoko, Sakakibara Ayako

    Journal of Clinical and Experimental Hematopathology   Vol. 61 ( 3 ) page: 173 - 179   2021

     More details

    Language:English   Publisher:The Japanese Society for Lymphoreticular Tissue Research  

    <p>Neoplastic programmed cell death ligand 1 (PD-L1) expression, activated by <i>PD-L1</i> gene alterations, is strongly associated with classic Hodgkin lymphoma (CHL). This association enabled a diagnostic consensus for lymphocyte-depleted CHL (LD-CHL), a previously enigmatic disease. We describe two patients with LD-CHL and primary extranodal disease. One patient was a 92-year-old female (Case #1) with a large mass that involved the uterus combined with swollen lymph nodes in the pelvic cavity. The second patient was a 76-year-old female (Case #2) with human T-cell leukemia virus type 1 (HTLV-1) who initially exhibited massive bone marrow involvement without peripheral lymphadenopathies. Biopsies of these tumors from the cervix uteri and bone marrow, respectively, revealed lesions rich in Hodgkin and Reed-Sternberg (H-RS) cells and diminished populations of other cell populations. Immunohistochemistry demonstrated that these H-RS cells expressed CD30, BOB1, and fascin, but not CD15, CD20, PAX5, or OCT2. They also expressed PD-L1, which led to our preferred diagnosis of LD-CHL in both patients. Epstein-Barr virus was associated with LD-CHL in Case #1, but not in Case #2. Both patients were deemed too frail for treatment. They died of disease at 1 (Case #1) and 15 months (Case #2) after the diagnosis. These findings highlight the abnormal biological behavior of this immune-escape-related lymphoid neoplasm in patients with immunodeficiency due to immune senescence and HTLV1 infection.</p>

    DOI: 10.3960/jslrt.21008

    PubMed

    CiNii Research

  16. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review

    Sakakibara Ayako, Kohno Kei, Ishikawa Eri, Suzuki Yuka, Tsuyuki Yuta, Shimada Satoko, Shimada Kazuyuki, Satou Akira, Takahara Taishi, Ohashi Akiko, Takahashi Emiko, Kato Seiichi, Nakamura Shigeo, Asano Naoko

    Journal of Clinical and Experimental Hematopathology   Vol. 61 ( 4 ) page: 182 - 191   2021

     More details

    Language:Japanese   Publisher:The Japanese Society for Lymphoreticular Tissue Research  

    <p>The programmed cell death 1 (PD1)/PD1 ligand (PD-L1) axis plays an important role in tumor cell escape from immune control and has been most extensively investigated for therapeutic purposes. However, PD-L1 immunohistochemistry is still not used widely for diagnosis. We review the diagnostic utility of PD-L1 (by clone SP142) immunohistochemistry in large-cell lymphomas, mainly consisting of classic Hodgkin lymphoma (CHL) and diffuse large B-cell lymphoma (DLBCL). Neoplastic PD-L1 (nPD-L1) expression on Hodgkin and Reed-Sternberg cells is well-established among prototypic CHL. Of note, EBV+ CHL often poses a challenge for differential diagnosis from peripheral T-cell lymphoma with EBV+ non-malignant large B-cells; their distinction is based on the lack of PD-L1 expression on large B-cells in the latter. The nPD-L1 expression further provides a good diagnostic consensus for CHL with primary extranodal disease conceivably characterized by a combined pathogenesis of immune escape of tumor cells and immunodeficiency. Compared with CHL, the nPD-L1 expression rate is much lower in DLBCL, highlighting some specific subgroups of intravascular large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and EBV+ DLBCL. They consist of nPD-L1-positive and -negative subgroups, but their clinicopathological significance remains to be elucidated. Microenvironmental PD-L1 positivity on immune cells may be associated with a favorable prognosis in extranodal DLBCL. PD-L1 (by SP142) immunohistochemistry has helped us to understand the immune biology of lymphoid neoplasms possibly related by immune escape and/or immunodeficiency. However, knowledge of these issues remains limited and should be clarified for diagnostic consensus in the future.</p>

    DOI: 10.3960/jslrt.21003

    Web of Science

    PubMed

    CiNii Research

  17. Nodal diffuse large B-cell lymphoma with neoplastic PD-L1 positivity, but without EBV association: Three cases highlighting an aspect of gray zone lymphoma. Reviewed

    Kohno K, Suzuki Y, Harada T, Sakai A, Takeuchi Y, Inagaki Y, Megahed NA, Takahara T, Satou A, Sakakibara A, Nakamura S

    Pathology international   Vol. 70 ( 9 ) page: 695 - 697   2020.9

     More details

    Language:English   Publisher:Pathology International  

    DOI: 10.1111/pin.12982

    Web of Science

    Scopus

    PubMed

  18. PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases. Reviewed

    Yamashita D, Shimada K, Kohno K, Kogure Y, Kataoka K, Takahara T, Suzuki Y, Satou A, Sakakibara A, Nakamura S, Asano N, Kato S

    Pathology international   Vol. 70 ( 8 ) page: 513 - 522   2020.8

     More details

    Language:English   Publisher:Pathology International  

    Inhibitors of programmed cell-death 1 (PD-1) and programmed cell-death ligand 1 (PD-L1) have revolutionized cancer therapy. Nodal cytotoxic T-cell lymphoma (CTL) is characterized by a poorer prognosis compared to nodal non-CTLs. Here we investigated PD-L1 expression in 50 nodal CTL patients, with and without EBV association (25 of each). We identified seven patients (14%) with neoplastic PD-L1 (nPD-L1) expression on tumor cells, including three males and four females, with a median age of 66 years. One of the seven cases was TCRαβ type, three were TCRγδ type and three were TCR-silent type. Six of the seven cases exhibited a lethal clinical course despite multi-agent chemotherapy, of whom four patients died within one year of diagnosis. Morphological findings were uniform, with six cases showing centroblastoid appearance. Among nPD-L1+ cases, two of three examined had structural variations of PD-L1 disrupting 3′-UTR region. Notably, all of the TCRγδ-type nodal CTL cases showed nPD-L1 or miPD-L1 positivity (3 and 10 cases, respectively). TCRγδ-type cases comprised 42% of nPD-L1+ cases (P = 0.043 vs. PD-L1−), and 35% of miPD-L1+ cases (P = 0.037 vs. PD-L1−). The results indicate that PD-L1+ nodal CTL cases, especially of the TCRγδ type, are potential candidates for anti-PD-1/PD-L1 therapies.

    DOI: 10.1111/pin.12950

    Web of Science

    Scopus

    PubMed

  19. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142. Reviewed

    Sakakibara A, Kohno K, Ishikawa E, Suzuki Y, Shimada S, Eladl AE, Elsayed AA, Daroontum T, Satou A, Takahara T, Ohashi A, Takahashi E, Kato S, Nakamura S, Asano N

    Pathology international   Vol. 70 ( 8 ) page: 481 - 492   2020.8

     More details

    Language:English   Publisher:Pathology International  

    Epstein–Barr virus (EBV) is prevalent among healthy individuals, and is implicated in numerous reactive and neoplastic processes in the immune system. The authors originally identified a series of senile or age-related EBV-associated B-cell lymphoproliferative disorders (LPD) bearing a resemblance to immunodeficiency-associated ones. These LPDs may be associated with immune senescence and are now incorporated into the revised 4th edition of 2017 WHO lymphoma classification as EBV-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS). These EBV+ B-cells often have a Hodgkin/Reed-Sternberg (HRS)-like appearance and are shared beyond the diagnostic categories of mature B-cell neoplasms, mature T-cell neoplasms, classic Hodgkin lymphoma, and immunodeficiency-associated LPD. In addition, peculiar new diseases, such as EBV+ mucocutaneous ulcer and EBV+ DLBCL affecting the young, were recognized. On the other hand, lymphoma classification is now evolving in accord with deeper understanding of the biology of programmed death ligand 1 (PD-L1). Assessing PD-L1 positivity by staining with the anti-PD-L1 monoclonal antibody SP142 provides new insight by discriminating between immune evasion and senescence or immunodeficiency. The aim of the present review is to briefly summarize the diagnostic use of immunostaining with SP142 in malignant lymphomas and/or LPDs that feature tumor and nonmalignant large B-cells harboring EBV.

    DOI: 10.1111/pin.12946

    Web of Science

    Scopus

    PubMed

  20. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy Reviewed

    Suzuki Yuka, Kohno Kei, Matsue Kosei, Sakakibara Ayako, Ishikawa Eri, Shimada Satoko, Shimada Kazuyuki, Mabuchi Seiyo, Takahara Taishi, Kato Seiichi, Nakamura Shigeo, Satou Akira

    CANCER MEDICINE   Vol. 9 ( 13 ) page: 4768 - 4776   2020.7

     More details

    Language:Japanese   Publisher:Cancer Medicine  

    Background: Intravascular large B-cell lymphoma (IVLBCL) is a rare form of diffuse large B-cell lymphoma (DLBCL) arising in extranodal sites. PD-L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains to be elucidated. Aims: This study was aimed to reveal the characteristics of PD-L1+ IVLBCL. Methods and results: Neoplastic PD-L1 expression was examined in 34 cases of IVLBCL and clinicopathological characteristics between patients with PD-L1+ and PD-L1− IVLBCL were compared. We assessed PD-L1 expression with SP142 antibody. Twelve (35%) of 34 cases showed positivity for PD-L1. The PD-L1+ group had significantly lower survival rates compared to the PD-L1− group. The PD-L1+ IVLBCL group also had a significantly lower age distribution and a lower frequency of patients older than 60 years compared to the PD-L1− group. Very recently, we speculate that there is possible link between PD-L1+ IVLBCL and PD-L1+ extranodal DLBCL-NOS (eDLBCL) because features of the two groups showed overlapping. Therefore, we compared the clinicopathological characteristics of the PD-L1+ IVLBCL and PD-L1+ eDLBCL. There were no significant differences in clinicopathological parameters and prognosis. Conclusion: The worse prognosis of the PD-L1+ group might be caused by immune evasion mechanisms, which are linked to PD-L1 expression. Therefore, PD-L1+ IVLBCL cases might be regarded as good candidates for targeted immunotherapy. We also highlighted the overlapping features of PD-L1+ IVLBCL and PD-L1+ eDLBCL. This result suggests that they should be regarded as one entity, immune evasion-related extranodal large B-cell lymphoma.

    DOI: 10.1002/cam4.3104

    Web of Science

    Scopus

    PubMed

  21. Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type. Reviewed

    Kohno K, Suzuki Y, Elsayed AA, Sakakibara A, Takahara T, Satou A, Kato S, Nakamura S, Asano N

    American journal of clinical pathology   Vol. 153 ( 5 ) page: 571 - 582   2020.4

     More details

    Language:English   Publisher:American Journal of Clinical Pathology  

    Objectives: We describe results of programmed death ligand 1 (PD-L1) immunohistochemical assessment in methotrexate (MTX)-associated lymphoproliferative disorders (LPDs) and highlight the characteristics of classic Hodgkin lymphoma (CHL) type MTX-LPD. Methods: Fifty cases of MTX-LPD, including CHL type (n = 9), diffuse large B-cell lymphoma type (n = 15), and polymorphic B-cell LPD (n = 21), were investigated. Results: Staining with anti-PD-L1 clone SP142 was exclusively found in CHL type (89%) but not in the others. Cases of CHL type MTX-LPD involved nodal disease and were associated with Epstein-Barr virus. They were histopathologically characterized by a vaguely nodular pattern, predominance of mononuclear cells, and strong expression of at least one pan-B-cell marker. Their clinical course was variable, with spontaneous regression in 5 patients, relapse in 2, and a fatal course in 1. Conclusions: The PD-L1 (clone SP142) workup aids the diagnostic approach to patients with MTX-LPD. CHL type MTX-LPD appears to represent a unique morphologic variant of CHL.

    DOI: 10.1093/ajcp/aqz198

    Web of Science

    Scopus

    PubMed

  22. Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry. Reviewed

    Kohno K, Sakakibara A, Iwakoshi A, Hasegawa M, Adachi S, Ishikawa E, Suzuki Y, Shimada S, Nakaguro M, Shimoyama Y, Takahara T, Takahashi E, Ohashi A, Satou A, Kato S, Asano N, Nakamura S

    Pathology international   Vol. 70 ( 2 ) page: 108 - 115   2020.2

     More details

    Language:English  

    DOI: 10.1111/pin.12888

  23. Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases. Reviewed

    Sakakibara A, Kohno K, Iwakoshi A, Moritani S, Fujishiro A, Kito K, Suzuki Y, Shimada S, Nakaguro M, Shimoyama Y, Takahara T, Takahashi E, Ohashi A, Satou A, Kato S, Asano N, Nakamura S

    Pathology international   Vol. 70 ( 2 ) page: 116 - 122   2020.2

     More details

    Language:English  

    DOI: 10.1111/pin.12891

  24. EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma Reviewed

    Eladl Ahmed E., Shimada Kazuyuki, Suzuki Yuka, Takahara Taishi, Kato Seiichi, Kohno Kei, Elsayed Ahmed Ali, Wu Chun-Chieh, Tokunaga Takashi, Kinoshita Tomohiro, Sakata-Yanagimoto Mamiko, Nakamura Shigeo, Satou Akira

    CANCER MEDICINE   Vol. 9 ( 2 ) page: 678 - 688   2020.1

     More details

    Language:Japanese   Publisher:Cancer Medicine  

    Epstein-Barr virus (EBV)-positive B cells have been detected in 66%-86% of patients with angioimmunoblastic T-cell lymphoma (AITL). However, it remains controversial whether EBV status has an impact on the survival of patients with AITL. In this study, we aimed to reevaluate the impact of EBV on the clinicopathological characteristics of AITL. In particular, we focused on the impact of EBV in younger patients with AITL. In total, 270 cases of AITL were studied. Epstein-Barr virus-positive B cells were detected in 191 (71%) cases (EBER+ group). Among the patients who received anthracycline-based therapy, the EBER status did not affect the overall survival (OS) or progression-free survival (PFS). In the younger group of AITL (≤60 years), PFS was significantly worse in the EBER− group compared to the EBER+ group (P =.0013). Furthermore, the multivariate analysis identified EBER-negative status, thrombocytopenia, and elevated serum IgA level as significant adverse prognostic factors for PFS (P <.001, P <.001, and P =.002). Based on these findings, we constructed new prognostic model for the younger group, based on three adverse factors. We classified the patients into two risk groups: low risk (no or 1 adverse factor) and high risk (2 or 3 adverse factors). This new model for younger patients with AITL showed that both OS and PFS were significantly related to the level of risk (P <.0001). In summary, this study showed that, among younger patients with AITL, an EBER+ status significantly improved prognosis compared to an EBER− status. Our new prognostic model should be applicable to younger patients with AITL.

    DOI: 10.1002/cam4.2742

    Web of Science

    Scopus

    PubMed

  25. Anaplastic variant of diffuse large B-cell lymphoma: Reappraisal as a nodal disease with sinusoidal involvement. Reviewed

    Megahed NA, Kohno K, Sakakibara A, Eladl AE, Elsayed AA, Wu CC, Suzuki Y, Takahara T, Kato S, Nakamura S, Satou A, Asano N

    Pathology international   Vol. 69 ( 12 ) page: 697 - 705   2019.12

     More details

    Language:English   Publisher:Pathology International  

    Anaplastic variant (av) of diffuse large B-cell lymphoma (DLBCL) is morphologically defined in the 2017 World Health Organization classification, but still an enigmatic disease in its clinicopathologic distinctiveness, posing the differential diagnostic problem from gray zone lymphoma (GZL) and classic Hodgkin lymphoma (cHL). Thirty-one cases previously diagnosed as avDLBCL were reassessed. Of these, 27 (87%) and 4 (13%) were node-based and extranodal diseases, respectively. They were further reclassified into nodal avDLBCL (n = 18), nodal CD30+ DLBCL with T-cell/histiocyte-rich large B-cell lymphoma-like features (CD30+ DLBCL-THRLBCL) (n = 6), GZL with features intermediate between DLBCL and cHL (n = 3) and CD30+ extranodal DLBCL, NOS (n = 4). The nodal avDLBCL cases had a sheet-like proliferation of large cells and/or Hodgkin/Reed-Sternberg (HRS)-like cells in 12 (67%) notably with a sinusoidal pattern in 16 (89%). They showed an expression of CD20 and/or CD79a in all and CD30 in 15 of 18. All of them were negative for PD-L1 on tumor cells, although HRS-like cells showed negativity or partial loss of other B-cell markers to varying degrees. The present study highlighted the distinctiveness of the nodal avDLBCL with sinusoidal pattern, but without neoplastic PD-L1 expression, which provide refined diagnostic criteria for a more precise pathologic and clinical characterization of this disease.

    DOI: 10.1111/pin.12871

    Scopus

    PubMed

  26. Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases Reviewed

    Satou Akira, Tabata Tetsuya, Miyoshi Hiroaki, Kohno Kei, Suzuki Yuka, Yamashita Daisuke, Shimada Kazuyuki, Kawasaki Tomonori, Sato Yasuharu, Yoshino Tadashi, Ohshima Koichi, Takahara Taishi, Tsuzuki Toyonori, Nakamura Shigeo

    MODERN PATHOLOGY   Vol. 32 ( 8 ) page: 1135 - 1146   2019.8

     More details

    Language:Japanese   Publisher:Modern Pathology  

    Methotrexate-associated lymphoproliferative disorders are categorized as “other immunodeficiency-associated lymphoproliferative disorders in the WHO classification. Methotrexate-associated lymphoproliferative disorder is mainly a B-cell lymphoproliferative disorders or Hodgkin lymphoma type, whereas T-cell lymphoproliferative disorders are relatively rare (4–8%). Only a small number of methotrexate-associated T-cell lymphoproliferative disorders have been detailed thus far. Because of the rarity, methotrexate-associated T-cell lymphoproliferative disorder has not been well studied and its clinicopathological characteristics are unknown. A total of 28 cases of methotrexate-associated T-cell lymphoproliferative disorders were retrospectively analyzed. Histologically and immunohistochemically, they were divided into three main types: angioimmunoblastic T-cell lymphoma (n = 19), peripheral T-cell lymphoma, NOS (n = 6), and CD8+ cytotoxic T-cell lymphoma (n = 3). Among the 28 cases, only one CD8+ cytotoxic T-cell lymphoma case was Epstein-Barr virus-positive. The other 27 cases were negative for Epstein-Barr virus on tumor cells, but scattered Epstein-Barr virus-infected B-cells were detected in 24 cases (89%), implying the reactivation of Epstein-Barr virus caused by immunodeficient status of the patients. After the diagnosis of methotrexate-associated T-cell lymphoproliferative disorder, methotrexate was immediately withdrawn in 26 cases. Twenty (77%) cases presented with spontaneous regression. Compared to methotrexate-associated B-cell lymphoproliferative disorder, patients with methotrexate-associated T-cell lymphoproliferative disorder had a significantly higher proportion of males (p = 0.035) and presence of B-symptoms (p = 0.036), and lower proportion of Epstein-Barr virus+ tumor cells (p < 0.001). Although the difference was not significant, the methotrexate-associated T-cell lymphoproliferative disorder also had more frequent spontaneous regression (p = 0.061). In conclusion, methotrexate-associated T-cell lymphoproliferative disorder was divided into three main types: angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, NOS, and CD8+ cytotoxic T-cell lymphoma. Angioimmunoblastic T-cell lymphoma was the most common type. Methotrexate-associated T-cell lymphoproliferative disorder was characterized by a high rate of spontaneous regression after methotrexate cessation. Epstein-Barr virus positivity was relatively rare in methotrexate-associated T-cell lymphoproliferative disorder, significantly less frequent than methotrexate-associated B-cell lymphoproliferative disorder, suggesting different pathogenesis.

    DOI: 10.1038/s41379-019-0264-2

    Web of Science

    Scopus

    PubMed

  27. Divergence and heterogeneity of neoplastic PD-L1 expression: Two autopsy case reports of intravascular large B-cell lymphoma Reviewed

    Sakakibara Ayako, Inagaki Yuichiro, Imaoka Eiki, Sakai Yu, Ito Masafumi, Ishikawa Eri, Shimada Satoko, Shimada Kazuyuki, Suzuki Yuka, Nakamura Shigeo, Satou Akira, Kohno Kei

    PATHOLOGY INTERNATIONAL   Vol. 69 ( 3 ) page: 148 - 154   2019.3

     More details

    Language:Japanese   Publisher:Pathology International  

    Intravascular large B-cell lymphoma (IVLBCL) is a distinct disease, but the neoplastic PD-L1 expression on tumor cells may vary among cases. We evaluated 10 IVLBCL autopsy cases for neoplastic PD-L1 expression, and had positive results in two cases. In one case, neoplastic PD-L1 expression (SP142, 28-8, and E1J2J clones) was dependent on the organ and anatomical site (capillaries vs. vessels) of the tumor tissue. Neoplastic PD-L1 expression was found in tumor cells located in capillaries in the central nervous system, pituitary gland, kidneys, lung, and gastrointestinal tract; sinuses/sinusoids of the spleen, liver, bone marrow, and lymph nodes; and an extravascular location. However, this expression was not detected in tumor cells located in the adrenal gland, thyroid gland, pancreas, ovaries, uterus, pleura, and small or larger-sized vessels of the lung. The other case showed constant neoplastic PD-L1 expression on the tumor cells, and in addition to the affected organs, capillaries, and vessels with two anti-PD-L1 antibodies (28-8 and E1J2J, but not SP142). The divergence and heterogeneity of neoplastic PD-L1 expression were clearly demonstrated in our cases. To the best of our knowledge, this is the first description of divergent neoplastic PD-L1 expression among the affected organs and anatomical sites in IVLBCL.

    DOI: 10.1111/pin.12757

    Web of Science

    Scopus

    PubMed

  28. Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma Reviewed

    Suzuki Yuka, Sakakibara Ayako, Shimada Kazuyuki, Shimada Satoko, Ishikawa Eri, Nakamura Shigeo, Kato Seiichi, Takahara Taishi, Asano Naoko, Satou Akira, Kohno Kei

    PATHOLOGY INTERNATIONAL   Vol. 69 ( 1 ) page: 13 - 20   2019.1

     More details

    Language:Japanese   Publisher:Pathology International  

    We identified six patients with Epstein-Barr virus (EBV)-negative extranodal diffuse large B-cell lymphoma (DLBCL) and immunohistochemical expression of PD-L1 on their tumor cells by examining 283 DLBCL cases with the PD-L1 SP142 clone between 2015 and 2017. They consisted of two men and four women with a median age of 71 years, and were examined in an autopsy (n = 1) and biopsies from the adrenal gland (n = 2), skin (n = 1), pelvic cavity (n = 1), and kidney (n = 1). All showed a monomorphic population of large transformed B-cells leading to diagnoses of DLBCL with two intravascular large B-cell lymphoma (IVLBCL) and one de novo CD5+ type and were featured by an invariable immunephenotype: CD3-, CD20+, BCL-2+, and MUM1+. In addition, CD5 and CD10 were each detected in one case. All cases expressed PD-L1 on >10% to >90% of tumor cells, which was confirmed with two other PD-L1 antibodies (E1J2J and 28-8). Three untreated patients had a rapid, lethal clinical course within 7 months after diagnosis; while, the remaining three achieved complete remission after treatment and were alive at the last follow-up. We suggest immune evasion-related extranodal large B-cell lymphoma should be recognized beyond the currently identified entities of IVLBCL and de novo CD5+ DLBCL.

    DOI: 10.1111/pin.12742

    Web of Science

    Scopus

    PubMed

  29. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells Reviewed

    Ishikawa Eri, Kato Seiichi, Shimada Kazuyuki, Tanaka Tsutomu, Suzuki Yuka, Satou Akira, Kohno Kei, Sakakibara Ayako, Yamamura Takeshi, Nakamura Masanao, Miyahara Ryoji, Goto Hidemi, Nakamura Shigeo, Hirooka Yoshiki

    CANCER MEDICINE   Vol. 7 ( 12 ) page: 6051 - 6063   2018.12

     More details

  30. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells. Reviewed

    Sakakibara A, Kohno K, Eladl AE, Klaisuwan T, Ishikawa E, Suzuki Y, Shimada S, Nakaguro M, Shimoyama Y, Takahara T, Kato S, Asano N, Nakamura S, Satou A

    Histopathology   Vol. 72 ( 7 ) page: 1156 - 1163   2018.6

     More details

    Language:English  

    DOI: 10.1111/his.13475

    PubMed

  31. Anaplastic variant of diffuse large B-cell lymphoma with hallmark cell appearance: Two cases highlighting a broad diversity in the diagnostics. Reviewed

    Sakakibara A, Kohno K, Kuroda N, Yorita K, Megahed NA, Eladl AE, Daroontum T, Ishikawa E, Suzuki Y, Shimada S, Nakaguro M, Shimoyama Y, Satou A, Kato S, Yatabe Y, Asano N, Nakamura S

    Pathology international   Vol. 68 ( 4 ) page: 251 - 255   2018.4

     More details

    Language:English  

    DOI: 10.1111/pin.12653

    PubMed

  32. Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression

    Sakakibara Ayako, Inagaki Yuichiro, Imaoka Eiki, Ishikawa Eri, Shimada Satoko, Shimada Kazuyuki, Suzuki Yuka, Nakamura Shigeo, Satou Akira, Kohno Kei

    Journal of Clinical and Experimental Hematopathology   Vol. 58 ( 1 ) page: 32 - 35   2018

     More details

    Language:Japanese   Publisher:The Japanese Society for Lymphoreticular Tissue Research  

    <p>Intravascular large B-cell lymphoma (IVLBCL) is a rare and clinically distinctive entity characterized by the almost exclusive growth of large cells within the lumen of blood vessels in particular capillaries. Reports of this peculiar disease, do not commonly address the PD-L1 expression on IVLBCL tumor cells. Here, we describe a 51-year-old Japanese woman who presented with rapidly progressive cognitive decline and higher brain dysfunction. CT scan and MRI revealed multiple ischemic foci in the cerebral hemispheres, ground-glass opacity in the lungs, and splenomegaly. Random skin biopsy for IVLBCL diagnosis yielded negative results. The patient experienced a rapidly deteriorating clinical course with no treatment, and died from the disease after 3 months of hospitalization. Post-mortem examination revealed systemic intravascular plugging of lymphoma cells, without mass lesions in the central nervous system or in visceral organs such as the lungs, liver, pituitary gland, ovaries, and uterus. The tumor cells were positive for CD10, CD20, BCL2, BCL6, and MUM1, but not other lineage-specific markers. Notably, the tumor cells showed strong PD-L1 expression. Our case was diagnosed as IVLBCL with neoplastic PD-L1 expression. These findings suggest that PD-L1 is associated with immune evasion of IVLBCL and may play a role in the pathogenesis and peculiar biological behavior of this unique disease. Additionally, PD-L1 may represent a possible therapeutic target for immune check-point inhibitors.</p>

    DOI: 10.3960/jslrt.17037

    Web of Science

    PubMed

    CiNii Research

  33. Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm Reviewed

    Suzuki K., Suzuki Y., Hama A., Muramatsu H., Nakatochi M., Gunji M., Ichikawa D., Hamada M., Taniguchi R., Kataoka S., Murakami N., Kojima D., Sekiya Y., Nishikawa E., Kawashima N., Narita A., Nishio N., Nakazawa Y., Iwafuchi H., Watanabe K-i, Takahashi Y., Ito M., Kojima S., Kato S., Okuno Y.

    LEUKEMIA   Vol. 31 ( 7 ) page: 1629 - 1633   2017.7

     More details

    Language:Japanese  

    DOI: 10.1038/leu.2017.101

    Web of Science

  34. RECURRENT MYB REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM Reviewed

    Suzuki K., Okuno Y., Suzuki Y., Hama A., Muramatsu H., Nakatochi M., Gunji M., Ichikawa D., Hamada M., Taniguchi R., Kataoka S., Murakami N., Kojima D., Sekiya Y., Nishikawa E., Kawashima N., Narita A., Nishio N., Nakazawa Y., Iwafuchi H., Watanabe K., Ito M., Kojima S., Kato S., Takahashi Y.

    HAEMATOLOGICA   Vol. 102   page: 35 - 35   2017.6

     More details

    Language:Japanese  

    Web of Science

  35. Clinicopathological Study of 30 Cases of Peripheral T-cell Lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan Reviewed

    Eladl Ahmed E., Satou Akira, Elsayed Ahmed Ali, Suzuki Yuka, Kato Seiichi, Asano Naoko, Nakamura Shigeo

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY   Vol. 41 ( 4 ) page: 506 - 516   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  36. Overexpression of monocyte chemoattractant protein-1 in the overlying epidermis of multicentric reticulohistiocytosis lesions: a case report Reviewed

    Hiroaki Iwata, Yuka Okumura, Mariko Seishima, Yumi Aoyama

    Int J Dermatol   Vol. 51 ( 4 ) page: 492 - 494   2012.4

     More details

    Language:English  

    DOI: 10.1111/j.1365-4632.2010.04573.x

▼display all

MISC 2

  1. Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases.

    Sakakibara A, Kohno K, Iwakoshi A, Moritani S, Fujishiro A, Kito K, Suzuki Y, Shimada S, Nakaguro M, Shimoyama Y, Takahara T, Takahashi E, Ohashi A, Satou A, Kato S, Asano N, Nakamura S

    Pathology international   Vol. 70 ( 2 ) page: 116 - 122   2020.2

     More details

    Language:English   Publisher:Pathology International  

    Composite lymphoma is a well-known diagnostic entity exhibiting the synchronous occurrence of two or more distinct types of lymphomas in the same specimen. Here we report two patients, a 14-year-old female (Case 1) and a 45-year-old male (Case 2), with mediastinal composite lymphoma, comprising nodular sclerosis classic Hodgkin lymphoma (NSCHL) and primary mediastinal large B-cell lymphoma (PMBL). Both patients had a mediastinal mass, and manifested two different histologic components in the same biopsy, one characteristic of NSCHL and the other PMBL. The NSCHL areas included Hodgkin and Reed–Sternberg (HRS) cells with typical immunophenotypic features (CD30-positive and CD20-negative), whereas the sheets of large tumor cells characteristic of PMBL were strongly and uniformly CD20-positive. Interestingly, although both cases showed neoplastic PD-L1 (nPD-L1) positivity on the HRS cells of NSCHL, they differed regarding nPD-L1 expression on the PMBL tumor cells. In Case 1, the nPD-L1-negative PMBL component was anatomically situated outside the NSCHL lesion. On the other hand, in Case 2, the nPD-L1-positive PMBL component was characterized by transitional or continuous areas with the NSCHL component. These findings suggested that nPD-L1 expression may define two subtypes of PMBL that are more similar to or distinct from classic Hodgkin lymphoma.

    DOI: 10.1111/pin.12891

    Scopus

    PubMed

  2. Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry.

    Kohno K, Sakakibara A, Iwakoshi A, Hasegawa M, Adachi S, Ishikawa E, Suzuki Y, Shimada S, Nakaguro M, Shimoyama Y, Takahara T, Takahashi E, Ohashi A, Satou A, Kato S, Asano N, Nakamura S

    Pathology international   Vol. 70 ( 2 ) page: 108 - 115   2020.2

     More details

    Language:English   Publisher:Pathology International  

    Although several reports have highlighted neoplastic PD-L1 (nPD-L1) expression in classic Hodgkin lymphoma (CHL), some have addressed associations between its expression and detailed histopathologic features. Here we describe four cases of syncytial variant of CHL (SV-CHL), with and without Epstein–Barr virus (EBV) association, and highlight the diagnostic utility of PD-L1 (clone SP142) immunohistochemistry. The patients were a 61-year-old male, 45-year-old male, 85-year-old female, and 89-year-old female. All presented with cervical or axillary lymphadenopathy, which on biopsy had the established histopathologic features of SV-CHL with a biphasic pattern of cohesive sheets of large tumor cells and typically scattered distribution of Hodgkin and Reed–Stenberg (HRS) cells. These tumor cells showed identical immunophenotypic findings for CD15, CD30, Fascin, PAX5, OCT2, BOB1 and EBV harboring, regardless of location. The exception was absent or decreased expression of nPD-L1 from tumor cells in the confluent sheets, contrasting with HRS cell positivity in typical areas of CHL. These findings offer the first suggestion of possible downregulation of nPD-L1 expression in association with the histopathologic progression of CHL. The results may be relevant for recognizing ‘confluent’ sheets in the diagnostic workup for SV-CHL.

    DOI: 10.1111/pin.12888

    Scopus

    PubMed